EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness

Shuyi Li, Shujiao He, Yongwei Su iD, Lei Wang, Yiran Wang, Yuanyuan Xu, Li Yu, Jingfeng Zhou iD

Proceedings of the National Academy of Sciences · 2026

DOI: 10.1073/pnas.2608310123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2026. Verfasst von Shuyi Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen University International Cancer Center, Department of Hematology and Oncology, Hematology Institution, Shenzhen University General Hospital,…. Hauptthemen laut MEDLINE: RUNX1 Translocation Partner 1 Protein, Core Binding Factor Alpha 2 Subunit, Oncogene Proteins, Fusion, Neoplastic Stem Cells. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: MOST | National Natural Science Foundation of China (NSFC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chromosomal translocations produce oncogenic fusion proteins such as AML1-ETO, which predominantly occupy gene promoters to induce transcriptional reprogramming in leukemia stem cells (LSCs), consequently driving the pathogenesis of t(8;21) acute myeloid leukemia (AML). However, whether AML1-ETO is recruited to additional regulatory DNA elements to orchestrate oncogenic gene expression programs has not been fully addressed. Here, we define AML1-ETO and H3K27ac CUT&Tag landscapes in primary t(8;21) AML CD34 + cells and t(8;21) AML cell lines, revealing AML1-ETO binding at a distal enhancer of the RNA N4-acetylcytidine (ac4C) writer N-acetyltransferase 10 (NAT10), thereby driving its transcriptional activation. Genetic ablation or pharmacological inhibition of NAT10 restricted the survival and self-renewal of LSCs in primary t(8;21) AML CD34 + cells, as well as in a retroviral AML1-ETO9a-driven t(8;21) AML mouse model, establishing NAT10 as a potential therapeutic vulnerability. Mechanistically, NAT10 is recruited to glutathione S-transferase omega 2 (GSTO2) mRNA to catalyze ac4C modification, thereby enhancing transcript stability and reprogramming glutathione metabolism, as demonstrated by ac4C profiling, RNA immunoprecipitation (RIP), and dCas13b-NAT10-based analyses. Silencing of GSTO2 in primary t(8;21) AML CD34 + cells decreased intracellular reduced glutathione (GSH) levels and compromised LSC survival and self-renewal, whereas GSTO2 overexpression or GSH supplementation largely rescued LSC maintenance following NAT10 loss. Collectively, these findings enrich and extend the understanding of AML1-ETO regulatory programs by linking distal enhancer activity to a NAT10–GSTO2 ac4C–GSH axis that integrates epigenomic, posttranscriptional, and metabolic reprogramming to sustain LSC stemness, highlighting this circuit as a potential therapeutic vulnerability in t(8;21) AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RUNX1 Translocation Partner 1 ProteinCore Binding Factor Alpha 2 SubunitOncogene Proteins, FusionNeoplastic Stem CellsGlutathioneLeukemia, Myeloid, AcuteHumansAnimalsEnhancer Elements, GeneticMiceChromosomes, Human, Pair 21Translocation, GeneticCell Line, TumorGene Expression Regulation, LeukemicChromosomes, Human, Pair 8

Stichwörter der Autor:innen

AML1-ETONAT10ac4Cleukemia stem cellst(8;21)

Substanzen

RUNX1 Translocation Partner 1 ProteinCore Binding Factor Alpha 2 SubunitOncogene Proteins, FusionAML1-ETO fusion protein, humanGlutathione

Autor:innen und Institutionen

  • Shenzhen University International Cancer Center, Department of Hematology and Oncology, Hematology Institution, Shenzhen University General Hospital, International Science and Technology Cooperation: Carson Cancer Stem…
  • Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.

ORCID-Profile: Yongwei Su, Jingfeng Zhou

Förderung

  • MOST | National Natural Science Foundation of China (NSFC)

Zitieren

APA

Li, S., He, S., Su, Y., Wang, L., Wang, Y., Xu, Y., Yu, L., & Zhou, J. (2026). AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2608310123

Vancouver

Li S, He S, Su Y, Wang L, Wang Y, Xu Y, et al. AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness. Proceedings of the National Academy of Sciences. 2026. doi:10.1073/pnas.2608310123

BibTeX
@article{Li2026,
  author = {Li, Shuyi and He, Shujiao and Su, Yongwei and Wang, Lei and Wang, Yiran and Xu, Yuanyuan and Yu, Li and Zhou, Jingfeng},
  title = {AML1-ETO hijacks a distal enhancer of NAT10 to reprogram glutathione metabolism and sustain leukemia stem cell stemness},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  doi = {10.1073/pnas.2608310123}
}
Kostenlos starten →